01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
03:33 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...
16:27 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Aridis amends IPO

Immunotherapy company Aridis Pharmaceuticals Inc. (San Jose, Calif.) amended its NASDAQ IPO on Aug. 6 and now plans to sell 2 million shares at $13-$15. The offering is being underwritten by Cantor Fitzgerald, Maxim, Laidlaw,...
16:36 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Aridis proposes $34.5M IPO

Infectious disease company Aridis Pharmaceuticals Inc. (San Jose, Calif.) proposed on July 18 to raise $34.5 million in an IPO on NASDAQ underwritten by Cantor, Maxim Group and Northland Capital Markets. The company's lead candidate...
19:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

Aridis, Shenzhen Hepalink form China JV

Aridis Pharmaceuticals Inc. (San Jose, Calif.) and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) formed a JV -- Shenzhen Arimab Biopharmaceuticals Co. Ltd. -- to develop and gain regulatory approval of two of Aridis’ candidates, Salvecin...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Aerucin: Phase I data

An open-label, U.S. Phase I trial in 16 healthy volunteers showed that single ascending doses of <=20 mg/kg IV Aerucin led to no serious adverse events. This year, Aridis plans to start an international Phase...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Salvecin regulatory update

FDA granted Fast Track designation to AR-301 from Aridis to treat hospital-acquired and ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus. The human IgG1 mAb against S. aureus alpha-hemolysin (aHL) generated using Aridis’ MabIgX technology is...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Aerucin regulatory update

FDA granted Fast Track designation to Aridis’ Aerucin to treat hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. The human IgG1 mAb against P. aeruginosa is in Phase I testing, with data expected next quarter....
01:07 , Jul 15, 2015 |  BC Extra  |  Company News

Management tracks

Baxalta Inc. (NYSE:BXLT) named Jacopo Leonardi EVP and president of immunology. Leonardi most recently was general manager of U.S. Hemophilia at the Baxter BioScience unit of Baxter International Inc. (NYSE:BAX). Antares Pharma Inc. (NASDAQ:ATRS) hired...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Aerucin: Phase I started

Aridis began an open-label, U.S. Phase I trial to evaluate single ascending doses of IV Aerucin in about 15 healthy adults. Aridis Pharmaceuticals Inc. , San Jose, Calif.   Product: Aerucin   Business: Infectious  ...